News ArticleGland Pharma Names Xiao Le Chief Investment Officer of Its Wholly-Owned Singapore Subsidiary
Appointment effective November 9, 2026, focusing on investment and M&A strategy across multiple international markets
Gland Pharma Limited announced the appointment of Mr. Xiao Le as Chief Investment Officer of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective November 9, 2026. He will lead investment initiatives and enhance merger and acquisition capabilities across the US, China, Singapore, and other markets, reporting directly to the subsidiary's CEO.
Gland Pharma Limited
Change in Management
Gland Pharma Limited has appointed Mr. Xiao Le as Chief Investment Officer at its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective November 9, 2026, to spearhead investments and enhance merger and acquisition strategies in key global markets.
Mr. Xiao Le brings over 15 years of investment and asset management experience concentrating in medical devices, biopharma, diagnostics, and healthcare services sectors.
He has held significant roles including Chief Financial Officer at MegaRobo Technologies (Singapore), Director on the Board at CANbridge Pharmaceuticals (USA), and Senior Director for M&A and Strategic Investments at Wuxi AppTec, among others.
His international experience spans working in Singapore, China, and the United States, supported by his education with a Bachelor's in Bio-engineering from The Johns Hopkins University and a Master's degree in Finance from MIT.
In his new role, he will report to the CEO of Gland Pharma International Pte. Ltd and focus on exploring investment opportunities and improving the company's M&A capabilities in the US, China, Singapore, and other countries.
Highlights
- Appointment effective November 09, 2026
- Role focused on investment and M&A initiatives
- Over 15 years of sector-specific international experience
- Reports to CEO of Gland Pharma International Pte. Ltd
- Educational background includes Johns Hopkins University and MIT
Key Data Snapshot
What happened
- Mr. Xiao Le appointed Chief Investment Officer of Gland Pharma International Pte. Ltd effective November 9, 2026.
- He will manage investment and M&A activities across the US, China, Singapore, and other countries.
Key details
- Mr. Xiao Le has over 15 years of experience in investments within medical devices, biopharma, diagnostics, and healthcare services.
- Previous roles include CFO of MegaRobo Technologies (Singapore), Director at CANbridge Pharmaceuticals (USA), and Senior Director at Wuxi AppTec.
- Educational qualifications include a Bachelor’s degree from The Johns Hopkins University and a Master’s degree from MIT.
- He will report to the CEO of Gland Pharma International Pte. Ltd.
Background and context
- Gland Pharma International Pte. Ltd is a wholly-owned subsidiary of Gland Pharma Limited.
- The appointment supports the subsidiary’s strategy to expand international investment and M&A capabilities.
Highlights
- Appointment effective November 09, 2026
- Role focused on investment and M&A initiatives
- Over 15 years of sector-specific international experience
- Reports to CEO of Gland Pharma International Pte. Ltd
- Educational background includes Johns Hopkins University and MIT
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI Circular No. HO/49/14/14(7)2025-CFD-POD/I/3762/2026 dated January 30, 2026
More News on Change in Management
View allLatest corporate announcements and market updates in Change in Management.
POWERGRID Names Shri Anupam Kumar as Government Nominee Director from November 6, 2026
POWERGRID Limited appointed Shri Anupam Kumar as Government Nominee Director on its Board, effective November 6, 2026, pursuant to an order from the Ministry of Power dated November 3, 2026.
Read Full Story
HDFC Bank Shareholders Approve Resolution via Postal Ballot E-Voting on November 6, 2026
HDFC Bank Limited announced that the resolution placed before its shareholders through a postal ballot was approved with the required majority on November 6, 2026, following electronic voting.
Read Full Story
Jubilant FoodWorks Extends Company Secretary Mona Aggarwal’s Resignation to March 31, 2027
Jubilant FoodWorks Limited has extended the resignation date of its Company Secretary and Key Managerial Personnel, Mona Aggarwal, to March 31, 2027. This extension allows for an orderly handover of her responsibilities prior to her planned departure from the company.
Read Full Story
